IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Core Insights - IGC Pharma, Inc. has announced the addition of a new clinical trial site for its Phase 2 study of IGC-AD1, aimed at treating agitation in Alzheimer's disease [1] Company Developments - The new clinical trial site, Ichor Research, is located in Syracuse, New York [1] - The Principal Investigator at the new site is Dr. Karl F. [1]